NVAX实时信号 | 通过Getagraph.com最大化利润

出售 66355 min ago

@ $5.28

发出时间: 14 Mar 2024 @ 02:02

回报率: -22.55%

上一信号: Mar 14 - 01:12

上一信号: 购买

回报率: 1.36 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs...

Stats
今日成交量	3.01M
平均成交量	7.13M
市值	572.41M
EPS	$0 ( 2024-02-28 )
下一个收益日期	( $-1.040 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.760
ATR14	$0.00800 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Trizzino John	Buy	144 000	Restricted Stock Units
2024-03-01	O'hara Elaine	Buy	120 000	Restricted Stock Units
2024-03-01	Kelly James Patrick	Buy	176 000	Restricted Stock Units
2024-03-01	Dubovsky Filip	Buy	144 000	Restricted Stock Units
2024-03-01	Casey Mark J	Buy	12 000	Restricted Stock Units

INSIDER POWER
62.98
Last 99 transactions
Buy: 1 952 927 \| Sell: 481 828

音量相关性

長: -0.13 (neutral)

短: -0.71 (moderate negative)

Signal:(49.895) Neutral

Novavax Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Novavax Inc 相关性 - 货币/商品

-0.29
( neutral )

-0.27
( neutral )

0.00
( neutral )

-0.32
( neutral )

Novavax Inc 财务报表

Annual	2023
营收:	$983.71M
毛利润:	$704.24M (71.59 %)
EPS:	$-5.41

FY	2023
营收:	$983.71M
毛利润:	$704.24M (71.59 %)
EPS:	$-5.41

FY	2022
营收:	$1.60B
毛利润:	$696.31M (43.55 %)
EPS:	$-8.42

FY	2021
营收:	$1.15B
毛利润:	$0.00 (0.00 %)
EPS:	$-23.44

Financial Reports:

No articles found.

Novavax Inc

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.